[8-K] Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Reports Material Event
The Pennant Group, Inc. (PNTG) – Form 144 filing discloses a proposed Rule 144 sale of 3,995 common shares, representing roughly 0.01 % of the 34.47 million shares outstanding. The shares carry an aggregate market value of $93,229.72 and are expected to be sold on or after 28 Jul 2025 through Fidelity Brokerage Services on the NASDAQ.
The securities were acquired via restricted-stock vesting on 25 Jul 2025 as compensation; no cash purchase was involved. The filer reports no other sales in the past three months and certifies that no undisclosed material adverse information exists. The notice contains no additional financial metrics or identity details of the seller.
The Pennant Group, Inc. (PNTG) – Comunicazione Form 144 rivela una proposta vendita ai sensi della Regola 144 di 3.995 azioni ordinarie, che rappresentano circa lo 0,01% delle 34,47 milioni di azioni in circolazione. Le azioni hanno un valore di mercato complessivo di 93.229,72 $ e si prevede che vengano vendute a partire dal 28 luglio 2025 tramite Fidelity Brokerage Services sul NASDAQ.
Le azioni sono state acquisite tramite vesting di azioni soggette a restrizioni il 25 luglio 2025 come compenso; non è stato effettuato alcun acquisto in contanti. Il dichiarante segnala nessuna altra vendita negli ultimi tre mesi e certifica che non esistono informazioni rilevanti negative non divulgate. La comunicazione non contiene ulteriori dati finanziari o dettagli sull’identità del venditore.
The Pennant Group, Inc. (PNTG) – Presentación del Formulario 144 revela una propuesta de venta bajo la Regla 144 de 3,995 acciones ordinarias, que representan aproximadamente el 0,01 % de las 34,47 millones de acciones en circulación. Las acciones tienen un valor de mercado agregado de $93,229.72 y se espera que se vendan a partir del 28 de julio de 2025 a través de Fidelity Brokerage Services en NASDAQ.
Los valores fueron adquiridos mediante la consolidación de acciones restringidas el 25 de julio de 2025 como compensación; no hubo compra en efectivo. El declarante informa que no ha realizado otras ventas en los últimos tres meses y certifica que no existe información adversa material no divulgada. El aviso no contiene métricas financieras adicionales ni detalles sobre la identidad del vendedor.
The Pennant Group, Inc. (PNTG) – Form 144 제출 내용은 약 0.01%에 해당하는 3,995 보통주의 규칙 144에 따른 매각 제안을 공개합니다. 총 발행 주식 3,447만 주 중 일부입니다. 해당 주식들의 총 시장 가치는 $93,229.72이며, 2025년 7월 28일 이후 NASDAQ의 Fidelity Brokerage Services를 통해 매각될 예정입니다.
해당 증권은 2025년 7월 25일 제한 주식 권리 확정(vesting)으로 보상받은 것으로, 현금 구매는 없었습니다. 제출자는 최근 3개월간 다른 매각이 없었음을 보고하며, 공개되지 않은 중대한 부정적 정보가 없음을 인증합니다. 공지에는 추가 재무 지표나 판매자 신원에 관한 정보는 포함되어 있지 않습니다.
The Pennant Group, Inc. (PNTG) – Dépôt du formulaire 144 révèle une vente proposée selon la règle 144 de 3 995 actions ordinaires, représentant environ 0,01 % des 34,47 millions d’actions en circulation. Les actions ont une valeur marchande totale de 93 229,72 $ et devraient être vendues à compter du 28 juillet 2025 via Fidelity Brokerage Services sur le NASDAQ.
Les titres ont été acquis par vesting d’actions restreintes le 25 juillet 2025 en tant que compensation ; aucun achat en espèces n’a été réalisé. Le déclarant indique aucune autre vente au cours des trois derniers mois et certifie qu’aucune information défavorable non divulguée n’existe. L’avis ne contient pas d’autres indicateurs financiers ni de détails sur l’identité du vendeur.
The Pennant Group, Inc. (PNTG) – Form 144 Meldung offenbart einen geplanten Verkauf von 3.995 Stammaktien gemäß Regel 144, was etwa 0,01 % der 34,47 Millionen ausstehenden Aktien entspricht. Die Aktien haben einen Gesamtmarktwert von 93.229,72 $ und sollen am oder nach dem 28. Juli 2025 über Fidelity Brokerage Services an der NASDAQ verkauft werden.
Die Wertpapiere wurden durch restricted-stock Vesting am 25. Juli 2025 als Vergütung erworben; kein Barkauf fand statt. Der Einreicher berichtet von keinen weiteren Verkäufen in den letzten drei Monaten und bestätigt, dass keine nicht offengelegten wesentlichen negativen Informationen vorliegen. Die Mitteilung enthält keine weiteren finanziellen Kennzahlen oder Angaben zur Identität des Verkäufers.
- Sale size is immaterial at ~0.01 % of shares outstanding, limiting potential market impact.
- Insider selling, even if small, can be perceived negatively by some investors tracking management’s trading activity.
Insights
TL;DR: Small, compensation-related Form 144 sale (<1 bps of float) appears routine and immaterial; neutral signal for PNTG shareholders.
This filing shows an insider’s intent to dispose of 3,995 newly-vested restricted shares worth about $93k. Given PNTG’s 34.5 M share base, the transaction equals roughly 0.012 % of outstanding common stock, posing negligible dilution or overhang risk. The absence of prior 3-month sales and the certification of no undisclosed adverse information further frame the trade as standard liquidity management. Without larger volume or contextual data (e.g., concurrent executive changes or guidance revisions), the event is not materially impactful to valuation or sentiment. I therefore classify the impact as neutral.
The Pennant Group, Inc. (PNTG) – Comunicazione Form 144 rivela una proposta vendita ai sensi della Regola 144 di 3.995 azioni ordinarie, che rappresentano circa lo 0,01% delle 34,47 milioni di azioni in circolazione. Le azioni hanno un valore di mercato complessivo di 93.229,72 $ e si prevede che vengano vendute a partire dal 28 luglio 2025 tramite Fidelity Brokerage Services sul NASDAQ.
Le azioni sono state acquisite tramite vesting di azioni soggette a restrizioni il 25 luglio 2025 come compenso; non è stato effettuato alcun acquisto in contanti. Il dichiarante segnala nessuna altra vendita negli ultimi tre mesi e certifica che non esistono informazioni rilevanti negative non divulgate. La comunicazione non contiene ulteriori dati finanziari o dettagli sull’identità del venditore.
The Pennant Group, Inc. (PNTG) – Presentación del Formulario 144 revela una propuesta de venta bajo la Regla 144 de 3,995 acciones ordinarias, que representan aproximadamente el 0,01 % de las 34,47 millones de acciones en circulación. Las acciones tienen un valor de mercado agregado de $93,229.72 y se espera que se vendan a partir del 28 de julio de 2025 a través de Fidelity Brokerage Services en NASDAQ.
Los valores fueron adquiridos mediante la consolidación de acciones restringidas el 25 de julio de 2025 como compensación; no hubo compra en efectivo. El declarante informa que no ha realizado otras ventas en los últimos tres meses y certifica que no existe información adversa material no divulgada. El aviso no contiene métricas financieras adicionales ni detalles sobre la identidad del vendedor.
The Pennant Group, Inc. (PNTG) – Form 144 제출 내용은 약 0.01%에 해당하는 3,995 보통주의 규칙 144에 따른 매각 제안을 공개합니다. 총 발행 주식 3,447만 주 중 일부입니다. 해당 주식들의 총 시장 가치는 $93,229.72이며, 2025년 7월 28일 이후 NASDAQ의 Fidelity Brokerage Services를 통해 매각될 예정입니다.
해당 증권은 2025년 7월 25일 제한 주식 권리 확정(vesting)으로 보상받은 것으로, 현금 구매는 없었습니다. 제출자는 최근 3개월간 다른 매각이 없었음을 보고하며, 공개되지 않은 중대한 부정적 정보가 없음을 인증합니다. 공지에는 추가 재무 지표나 판매자 신원에 관한 정보는 포함되어 있지 않습니다.
The Pennant Group, Inc. (PNTG) – Dépôt du formulaire 144 révèle une vente proposée selon la règle 144 de 3 995 actions ordinaires, représentant environ 0,01 % des 34,47 millions d’actions en circulation. Les actions ont une valeur marchande totale de 93 229,72 $ et devraient être vendues à compter du 28 juillet 2025 via Fidelity Brokerage Services sur le NASDAQ.
Les titres ont été acquis par vesting d’actions restreintes le 25 juillet 2025 en tant que compensation ; aucun achat en espèces n’a été réalisé. Le déclarant indique aucune autre vente au cours des trois derniers mois et certifie qu’aucune information défavorable non divulguée n’existe. L’avis ne contient pas d’autres indicateurs financiers ni de détails sur l’identité du vendeur.
The Pennant Group, Inc. (PNTG) – Form 144 Meldung offenbart einen geplanten Verkauf von 3.995 Stammaktien gemäß Regel 144, was etwa 0,01 % der 34,47 Millionen ausstehenden Aktien entspricht. Die Aktien haben einen Gesamtmarktwert von 93.229,72 $ und sollen am oder nach dem 28. Juli 2025 über Fidelity Brokerage Services an der NASDAQ verkauft werden.
Die Wertpapiere wurden durch restricted-stock Vesting am 25. Juli 2025 als Vergütung erworben; kein Barkauf fand statt. Der Einreicher berichtet von keinen weiteren Verkäufen in den letzten drei Monaten und bestätigt, dass keine nicht offengelegten wesentlichen negativen Informationen vorliegen. Die Mitteilung enthält keine weiteren finanziellen Kennzahlen oder Angaben zur Identität des Verkäufers.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices) (Zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The Capital Market | ||||
| The Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Amended Series F Convertible Preferred Stock Certificate of Designation
On July 28, 2025, after obtaining the approval of the Board of Directors and majority stockholder of Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the “Company”) as disclosed in the Company’s Definitive Information Statement on Schedule 14C filed with the Securities and Exchange Commission on July 7, 2025 (the “Schedule 14C”), the Company filed an Amended and Restated Certificate of Designations, Preferences, Rights and Limitations of Series F Convertible Preferred Stock (the “Restated Certificate of Designation”) with the Secretary of State of the State of Delaware. The Restated Certificate of Designation became effective upon filing.
As described in the Schedule 14C, the Series F Certificate of Designation provided that the Series F Convertible Preferred Stock could not be converted or voted in a manner that would result in the holder or his or her transferees or their affiliates holding or voting more than the lower of (i) the maximum percentage of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon conversion of the Series F Convertible Preferred Stock that could be issued to the holder without requiring a vote of the stockholders of the Company under the rules and regulations of The Nasdaq Capital Market, and (ii) 4.99% of the number of shares of common stock outstanding immediately before the original issue date (the “Series F Ownership Limitation”), prior to the date that the Company’s stockholders approved the issuance of shares of common stock to the holder thereof. The Restated Certificate of Designation removes such Series F Ownership Limitation so that the shares of Series F Convertible Preferred Stock may be converted and voted without regard to such Series F Ownership Limitation.
Except for the removal of the Series F Ownership Limitation, the Restated Certificate of Designation does not make any other changes to the Series F Certificate of Designation.
A copy of the Restated Certificate of Designation is attached hereto as Exhibit 3.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Exhibit | |
| 3.1 | Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series F Preferred Stock filed with the Secretary of State of the State of Delaware on July 28, 2025. | |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: July 28, 2025 | Cyclacel Pharmaceuticals, Inc. | |
| By: | /s/ Datuk Dr. Doris Wong Sing Ee | |
| Name: | Datuk Dr. Doris Wong Sing Ee | |
| Title: | Chief Executive Officer and Executive Director | |
| 3 |
FAQ
How many PNTG shares are being sold under this Form 144?
What is the estimated market value of the proposed PNTG sale?
When is the planned sale date for these Pennant Group shares?
How were the shares acquired by the insider?
What percentage of PNTG's outstanding shares does this sale represent?
